Evidence map›Paper›PMID 40380261›Full record

ReviewJournal of nanobiotechnology2025

Advances in microneedle-based drug delivery system for metabolic diseases: structural considerations, design strategies, and future perspectives.

Yao Li, Qiu Chen, Tingting Wang, Zengkai Ji, Sagar Regmi, Haibin Tong, Jian Ju, Aifang Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Programmable Self-Heating Microneedle Patch for on-Demand Postprandial Glucose Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yao Li *Zhejiang Provincial Key Laboratory for Water Environment and Marine Biological Resources Protection, College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035, China.
Qiu Chen *Department of Endocrinology, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325200, China.
Tingting WangWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China.
Zengkai JiWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China.
Sagar RegmiDepartment of Radiation Oncology, University Hospital Seidman Cancer Center Cleveland, Cleveland, OH, 44106, USA.
Haibin TongZhejiang Provincial Key Laboratory for Water Environment and Marine Biological Resources Protection, College of Life and Environmental Science, Wenzhou University, Wenzhou, 325035, China. tonghaibin@gmail.com.
Jian JuWenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, 325001, China. jujian@ucas.ac.cn.
Aifang WangThe People's Hospital of Yuhuan (Yuhuan People's Hospital Health Community Group), Taizhou, 317600, China. wangaifang19832024@163.com.

Funding

start-up grant from the Wenzhou Institute, University of Chinese Academy of Sciences WIUCASQD2021027Wenzhou Public Welfare Basic Research Program S20220021Zhejiang Provincial Natural Science Foundation of China LTGY23B050002
6 · The paper itself

Abstract

As the prevalence of metabolic diseases such as diabetes and obesity continue to rise, the search for more effective and convenient treatments has become a crucial issue in medical research. Microneedles (MNs), as an innovative drug delivery system, have shown advantages in the treatment of metabolic diseases in recent years. MNs-based drug delivery system, which use MNs to deliver drugs directly to the subcutaneous tissue, improve drug bioavailability and reduce systemic side effects. This review aims to summarize the latest concepts, designs, and types of MNs, and to investigate the materials and manufacturing methods used in their construction. Subsequently, the mechanisms of drug delivery and graded release of MNs and recent research progress are further summarized. This article focuses on the application of MNs in the treatment of common metabolic diseases, with a special emphasis on the progress and optimization of diabetic and anti-obesity MNs. The main challenges and future perspectives in the production and evaluation of MNs, as well as in enhancing treatment efficacy and improving safety, are elucidated.

Indexed as

Drug Delivery SystemsMetabolic DiseasesMicroinjectionsNeedlesAnimalsEquipment DesignHumansObesityControlled releaseDrug carrierMetabolic disease treatmentMetabolic syndromeMicroneedlesTransdermal drug delivery

Identifiers

PMID40380261
PMCPMC12083184

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.